Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool

Background. Prior to 2014, treatment for hepatitis C was limited. However, the subsequent introduction of direct acting antiviral medications (DAA) against hepatitis C led to improvements in morbidity and better medication tolerance. DAA therapy allowed for an increase in treatment rates of hepatiti...

Full description

Bibliographic Details
Main Authors: Jennifer Keller, Gary Marklin, Obi Okoye, Roshani Desai, Tej Sura, Ajay Jain, Chintalapati Varma, Mustafa Nazzal
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Journal of Transplantation
Online Access:http://dx.doi.org/10.1155/2021/6612453
id doaj-8557e8cc22aa4bd4b05ba59289adb031
record_format Article
spelling doaj-8557e8cc22aa4bd4b05ba59289adb0312021-02-15T12:53:07ZengHindawi LimitedJournal of Transplantation2090-00072090-00152021-01-01202110.1155/2021/66124536612453Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor PoolJennifer Keller0Gary Marklin1Obi Okoye2Roshani Desai3Tej Sura4Ajay Jain5Chintalapati Varma6Mustafa Nazzal7Division of Abdominal Transplant, Saint Louis University, St. Louis, MO, USAMid-America Transplant Services, St. Louis, MO, USADivision of Abdominal Transplant, Saint Louis University, St. Louis, MO, USADivision of Hepatology, Saint Louis University, St. Louis, MO, USASaint Louis University School of Medicine, St. Louis, MO, USASaint Louis University School of Medicine, St. Louis, MO, USADivision of Abdominal Transplant, Saint Louis University, St. Louis, MO, USADivision of Abdominal Transplant, Saint Louis University, St. Louis, MO, USABackground. Prior to 2014, treatment for hepatitis C was limited. However, the subsequent introduction of direct acting antiviral medications (DAA) against hepatitis C led to improvements in morbidity and better medication tolerance. DAA therapy allowed for an increase in treatment rates of hepatitis C in patients on the liver transplant waiting list. With the popularization of DAA, there became a growing concern about the utility of hepatitis C-positive (HCV+) deceased liver donors, especially after treating HCV+ potential recipients on the transplant waiting list. Methods. This is a retrospective, observational study using Mid-America Transplant Services (MTS) database from 2008 to 2017. Comparison was made before the widespread use of DAAs 2008–2013 (pre-DAA) against their common practice use 2014–2017 (post-DAA). All deceased liver donors with HCV antibody or nucleic acid positive results were evaluated. Results. Between 2008 and 2017, 96 deceased liver donors were positive for HCV. In the pre-DAA era, 47 deceased liver donors were positive for HCV, of which 32 (68.1%) were transplanted and 15 (31.9%) were discarded. In the post-DAA era, a total of 49 HCV+ organs were identified, out of which 43 (87.8%) livers were transplanted and 6 (12.2%) were discarded. Discard rate was significantly higher in the pre-DAA population (31.9% vs. 12.2%, p = 0.026). Secondary analysis showed a distinct trend towards increased regional sharing and utilization of HCV+ donors. Conclusion. In order to reduce discard rates of HCV+ patients, our data suggest that transplant centers could potentially delay HCV treatment in patients on the transplant waitlist.http://dx.doi.org/10.1155/2021/6612453
collection DOAJ
language English
format Article
sources DOAJ
author Jennifer Keller
Gary Marklin
Obi Okoye
Roshani Desai
Tej Sura
Ajay Jain
Chintalapati Varma
Mustafa Nazzal
spellingShingle Jennifer Keller
Gary Marklin
Obi Okoye
Roshani Desai
Tej Sura
Ajay Jain
Chintalapati Varma
Mustafa Nazzal
Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool
Journal of Transplantation
author_facet Jennifer Keller
Gary Marklin
Obi Okoye
Roshani Desai
Tej Sura
Ajay Jain
Chintalapati Varma
Mustafa Nazzal
author_sort Jennifer Keller
title Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool
title_short Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool
title_full Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool
title_fullStr Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool
title_full_unstemmed Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool
title_sort treatment of hepatitis c post-liver transplantation could mitigate discard rates of hepatitis c-positive deceased donor livers and expand the donor pool
publisher Hindawi Limited
series Journal of Transplantation
issn 2090-0007
2090-0015
publishDate 2021-01-01
description Background. Prior to 2014, treatment for hepatitis C was limited. However, the subsequent introduction of direct acting antiviral medications (DAA) against hepatitis C led to improvements in morbidity and better medication tolerance. DAA therapy allowed for an increase in treatment rates of hepatitis C in patients on the liver transplant waiting list. With the popularization of DAA, there became a growing concern about the utility of hepatitis C-positive (HCV+) deceased liver donors, especially after treating HCV+ potential recipients on the transplant waiting list. Methods. This is a retrospective, observational study using Mid-America Transplant Services (MTS) database from 2008 to 2017. Comparison was made before the widespread use of DAAs 2008–2013 (pre-DAA) against their common practice use 2014–2017 (post-DAA). All deceased liver donors with HCV antibody or nucleic acid positive results were evaluated. Results. Between 2008 and 2017, 96 deceased liver donors were positive for HCV. In the pre-DAA era, 47 deceased liver donors were positive for HCV, of which 32 (68.1%) were transplanted and 15 (31.9%) were discarded. In the post-DAA era, a total of 49 HCV+ organs were identified, out of which 43 (87.8%) livers were transplanted and 6 (12.2%) were discarded. Discard rate was significantly higher in the pre-DAA population (31.9% vs. 12.2%, p = 0.026). Secondary analysis showed a distinct trend towards increased regional sharing and utilization of HCV+ donors. Conclusion. In order to reduce discard rates of HCV+ patients, our data suggest that transplant centers could potentially delay HCV treatment in patients on the transplant waitlist.
url http://dx.doi.org/10.1155/2021/6612453
work_keys_str_mv AT jenniferkeller treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT garymarklin treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT obiokoye treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT roshanidesai treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT tejsura treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT ajayjain treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT chintalapativarma treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
AT mustafanazzal treatmentofhepatitiscpostlivertransplantationcouldmitigatediscardratesofhepatitiscpositivedeceaseddonorliversandexpandthedonorpool
_version_ 1714866510468481024